BEACH301 Clinical Trial: Targeted Achondroplasia Treatment for Children

Why does advancing targeted therapies for skeletal dysplasia require both scientific leadership and specialized clinical expertise?

Children’s Hospital Colorado recently enrolled the first two patients globally in the BEACH301 study. This study started by examining injectable daily medications for achondroplasia and is now progressing to daily oral medications for care. As the highest enrolling institution for this study, this early participation highlights the strength of our Skeletal Dysplasia Program. Here, multidisciplinary specialists like Klane White, MD, provide coordinated, lifelong care and promising new therapies to children with achondroplasia. And in this study, Dr. White and his colleagues are taking aim at the underlying causes of achondroplasia.

What are the genetic causes of achondroplasia?

A mutation in the FGFR3 gene causes achondroplasia. The FGFR3 gene is a fibroblast growth factor receptor, which is a group of receptor tyrosine kinases that play a vital role in bone growth regulation. Since we know this particular change in the FGFR3 gene causes achondroplasia, it gives researchers a target for disease-modifying therapies and hope for children with achondroplasia for treatment that does more than just manage symptoms.

What is the BEACH301 clinical trial for achondroplasia?

BEACH301 is a phase 2/3 clinical trial studying an oral therapy for children ages 3 to 10 with achondroplasia. Its goal is to test the safety and effectiveness of a medication called dabogratinib (TYRA-300), designed to target the underlying biology of achondroplasia. The trial is primarily looking at whether the drug can:

• Support healthy increases in height over time
• Change the FGFR3 signaling pathway that is overactive in this condition and limits bone growth
• Be safe for long-term use
• Potentially reduce other complications associated with this form of skeletal dysplasia

Two groups of children are enrolled — those with no former therapies and those who have previously received growth-accelerating therapy. As an open-label study, all children who participate will receive dabogratinib. Further, BEACH301 is a dose-escalation trial, meaning some participants will gradually receive more medication until they reach the highest level of safe administration.

What is dabogratinib?

Dabogratinib is a once-daily oral FGFR3 selective inhibitor that could influence the FGFR3 signal pathway and allow for healthy bone growth. Researchers are also testing it in other clinical trials for FGFR3-driven cancers.

Why is this research important for children with achondroplasia?

This experimental therapy is exciting to clinicians, children and families because it targets the FGFR3 receptor that contributes to achondroplasia, representing a more targeted approach than treatments focused solely on managing complications or symptoms.

Research into targeted therapies for conditions like achondroplasia is important because historically, care has focused on monitoring growth and managing complications rather than addressing the underlying molecular pathway. Inhibitors like dabogratinib may help modify the condition’s biology, with the potential to influence growth patterns and reduce other associated orthopedic, neurologic and respiratory concerns. The BEACH301 study, and others like it, represent a shift toward earlier interventions and more individualized care while improving long-term outcomes and quality of life for children with skeletal dysplasia.

What is the future for the BEACH301 clinical trial?

The BEACH301 trial is ongoing, with early participation milestones already underway. The first enrolled patient recently reached the six-month study point, which marks an important step in evaluating growth trends, safety and overall response to the therapy. As the study continues, researchers will monitor participants to better understand treatment effects over time. Further findings from BEACH301 and related studies may help inform care strategies and contribute to the emerging field of targeted therapies for children with achondroplasia and other skeletal dysplasia conditions.